tbuckley/cabot-search huggingface dataset:
FRI0086 Fatigue in Patients with Rheumatoid Arthritis Selected for Biological Treatment in the Daily Clinic: Associations with Classical Measures of Disease Activity
Authors: E.L. Egsmose, O.R. Madsen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The nature of the fatigue frequently experienced by patients with inflammatory joint diseases is not well understood (ref.). <h3>Objectives</h3> The purpose of the present study was to examine associations between fatigue (FTG) and classical measures of disease activity in rheumatoid arthritis (RA) patients selected for initiation of biological treatment. <h3>Methods</h3> Data on 221 RA patients planned to initiate treatment with a biological agent due to high and uncontrolled disease activity were extracted from the Danish registry for biological treatment in rheumatology (DANBIO). Simple linear correlation analyses (Pearson9s r) were used to assess the relationship between FTG as assessed on a visual analogue scale (VAS) (range 0-100) and classical measures of disease activity [swollen and tender joints, CRP, VAS global assessment of physician (PhGl) and patient (PaGl), VAS pain, HAQ], and the composite score DAS28-CRP and age. The best predictors of FTG were identified using stepwise multiple regression analysis. 95% lower and upper limits of agreement (LLoA and ULoA) with VAS patient global and VAS pain and the corresponding biases were obtained from Bland-Altman analyses. <h3>Results</h3> Mean age was 57±14 years, mean DAS28 5.0±0.9 and mean FTG 60.7±22.7. FTG was most strongly correlated with PaGl (r =0.83), pain (r =0.75) and HAQ (r =0.41) (all p&lt;0.0001) and most weakly with CRP (r =0.04, NS) and PhGl (r =0.03, NS). The most important predictor of FTG was PaGl (beta =0.68, p&lt;0.0001) followed by VAS pain (beta =0.18, p&lt;0.05) (R<sup>2</sup>=0.70, p&lt;0.0001). No other measures added significantly to the regression equation. Results were unchanged after leaving out DAS28-CRP. The bias [LLoA; ULoA] for FTG versus PaGl was -2.9±13.1 (p&lt;0.001) [-28.6; 22.8] and for FTG versus VAS pain 2.3±16.1 (p&lt;0.001) [-29.3; 33.6]. <h3>Conclusions</h3> FTG was poorly explained by objective measures of disease activity. The most important predictors were PaGl and VAS pain but although these two measures were nearly identical with FTG on the group level, large intra-individual differences were observed. The findings emphasise the complexity of understanding and dealing with FTG in the daily RA clinic. <h3>References</h3> Nikolaus S et al. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2013; 65: 1128-46. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2714
Tips for a Physician in Getting the Right Job Part III
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2013)

It is important that physicians are appropriately aggressive in obtaining the best possible job, and not sitting back passively and expecting employers to come hunting for them. Networking is very important to learn of new job opportunities and in some cases to be introduced to prospective employers. Social media sites may be useful for networking and for researching job opportunities and the people in certain organizations. Recruiters can be helpful for many physicians in finding the right job. However, some recruiters can be bothersome and be more interested in making a commission than in obtaining the best match between the employer and employee. Having stellar references who will give an enthusiastic recommendation for the job seeker, both in writing and on the phone, is very important.
Ossification of the Ligamentum Flavum Demonstrated by Tc-99m MDP SPECT Imaging of the Thoracic Spine
Authors: GEOFFREY R. STOREY, LLOYD RIDLEY, HANS VAN DER WALL
Journal: Clinical Nuclear Medicine (2001)

STOREY, GEOFFREY R. M.B., B.S., F.R.A.C.P.; RIDLEY, LLOYD M.B., B.S., F.R.A.C.R.; VAN DER WALL, HANS M.B., B.S., Ph.D., F.R.A.C.P. Author Information
Biliary Tract FDG Uptake Secondary to Stent Placement
Authors: EUGENE C. LIN, MATTHEW STUDLEY
Journal: Clinical Nuclear Medicine (2003)

From the Department of Radiology, Virginia Mason Medical Center, Seattle, Washington Received September 12, 2002. Accepted October 7, 2002. Correspondence: Eugene C. Lin, Department of Radiology, Virginia Mason Medical Center, Mailstop C5-XR, 1100 Ninth Avenue, P. O. Box 900, Seattle, Washington 98111. E-mail: [email protected]
FRI0456 Risk of Malignancy in Anca-Associated Vasculitis Patients
Authors: C. Rahmattulla, A. Göçeroğlu, M.E. Reinders, E.C. Hagen, J.A. Bruijn, I.M. Bajema
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Recent studies indicate that patients with ANCA-associated vasculitis (AAV) have a significantly higher risk of developing malignancies<sup>1</sup>, that the mortality in AAV patients is 2.6 times higher than that of the general population, and that malignancies are the second cause of death after the first year of diagnosis<sup>2</sup>. Drawbacks from these studies are a relatively short follow-up, and possibly, under-reportage due to lack of access to registries. <h3>Objectives</h3> To assess the risk of developing at least one malignancy after diagnosis of AAV. <h3>Methods</h3> We investigated the occurrence of malignancies in 187 histologically confirmed AAV patients after diagnosis at our center between 1982 and 2011 by performing a search in PALGA, a Dutch national pathology database which covers all the histologically confirmed malignancies diagnosed in The Netherlands. <h3>Results</h3> One hundred and thirty-six patients with AAV had a follow-up of at least 1 year; 46 of those developed 93 malignancies during a mean follow-up of 12.3 years. There were 63 non-melanoma skin cancers (NMSC) of the skin. Thirteen malignancies occurred more than once: four of the bladder, four of the prostate, three of colon/rectum and two of the lung. There was a variety of one time occurring malignancies. The mean age of AAV patients developing a malignancy was similar to patients without a malignancy (58 years). <h3>Conclusions</h3> This study shows a higher incidence of malignancies than was reported for a European study group. One explanation for this discrepancy could be the accurate data reporting through the Dutch PALGA system by which virtually no malignancy could have been missed. There was no significant age difference between patients with and without malignancies. Notably, there was a high number of NMSCs which is most likely related to the immunosuppressive therapy these patients receive. In the management and treatment of patients with AAV, it is of major importance to monitor closely for developing malignancies. <h3>References</h3> Heijl C., Harper L., Flossmann O., and al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials Ann Rheum Dis 2011; 70: 1415-1421. Flossmann O., Berden A., de Groot K., and al. Long-term patient survival in ANCA-associated vasculitis Ann Rheum Dis 2011; 70: 488-494. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5700
Abstract 1933: Adoptive T cell therapy shifts the secretion ability of cytokines to Th1 and decreases the number of Tregs in patients with cancer
Authors: Takeshi Ishikawa, Satoshi Kokura, Tsuguhiro Matsumoto, Jun Funaki, Satoko Adachi, Tetsuya Okayama, Naohisa Yoshida, Kazuhiko Uchiyama, Tomohisa Takagi, Osamu Handa, Hideyuki Konishi, Nobuaki Yagi, Naoki Wakabayashi, Yuji Naito, Toshikazu Yoshikawa, Naoyuki Sakamoto, Mari Tanigawa, Kazuko Uno
Journal: Cancer Research (2010)

Abstract [Aim] We analyzed the secretion ability of cytokines from peripheral blood mononuclear cells (PBMC) and the number of peripheral blood Tregs before and after adoptive T cell therapy (CD3-LAK) in order to assess the relation of the immunological responses and the efficacy of the treatment. [Method] Patients who received CD3-LAK treatment more than four times were done an entry of this study. We conducted this study after having obtained the informed consent of the study for these patients. We measured the secretion ability of cytokines from PBMC using the peripheral blood collected from the patients before treatment and 2 weeks later after the 4th treatment. The methods we measured the secretion ability of cytokines are shown below. IFN-alpha: We stimulated the whole blood by Sendai virus for 20 hours, and IFN-alpha of supernatant was measured by bioassay. The other cytokines (IL-2, IL-4, IL-10, TNF-alpha, IFN-gamma etc): We stimulated the whole blood by PHA for 48 hours, and the cytokines of supernatant were measured by BioPlex array. In terms of the change of the number of peripheral blood Tregs, we analyzed Foxp3 and CD4 positive T cells by flow cytometry. [Result] The values of IFN-gamma and TNF-alpha were significantly high after the treatment. Ratio of Treg to CD4 was significantly low after the treatment. The survival time of the group of patients in whom the number of Treg decreased after the treatment was longer than that of the other group of patients. [Discussion] We found that even in patients with refractory advanced cancer, the therapeutic intervention of CD3-LAK makes positive change - the secretion ability of cytokines from PBMC shifts to Th1, the number of Treg in peripheral blood decreases. And it suggests that adoptive T cell therapy influences immunoescape mechanism in patients with cancer. It will be necessary to clarify the mechanism of the effect and to develop an adoptive immunotherapy which has more beneficial clinical effect. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1933.
Identification of Brcaness in Sporadic Breast Cancers Using a Model that Integrates Multiple Assays
Authors: G.N. Madhumathy, K. Aruna, J.S. Prabhu, K. Desai, S. Manjunath, M. Correa, B.S. Srinath, K.S. Gopinath, N. Dendukuri, T.S. Sridhar
Journal: Annals of Oncology (2013)
Abstract 5301: Development of CAIX and CAXII targeting imaging probes for non-invasive detection of metastatic breast cancer in axillary lymph nodes
Authors: Narges K. Tafreshi, Marilyn M. Bui, Kellsey Bishop, Mark C. Lloyd, Steven A. Enkemann, Josef Vagner, Stephen R. Grobmyer, Robert J. Gillies, David L. Morse
Journal: Cancer Research (2011)

Abstract Axillary lymph node (ALN) status is the most important prognostic factor for staging breast cancer. ALNs are routinely excised for evaluation which is an invasive procedure associated with serious morbidities. The current study aims to develop a targeting platform for the non-invasive detection of metastatic breast cancer in lymph nodes. If successful, such an approach would decrease unnecessary surgery and significantly reduce associated morbidity. Two cell surface carbonic anhydrase isozymes (CAIX and/or CAXII) were identified by comparison of the gene expression profiles of lesions from breast cancer patients and benign breast tissue and confirmed with public databases and literature. Protein expression was validated by immunohistochemistry of patient tissue samples in tissue microarray. Together, these two markers detect 100% of the metastatic breast cancer to lymph nodes surveyed (n = 37). Targeted probes were developed by conjugation of CAIX and CAXII specific monoclonal antibodies (mAbs) to a near-infrared fluorescent dye (VivoTag 680, VisEn). The selectivity of the probes were determined by comparing their binding to expressing and non-expressing breast cancer cells in vitro and by intravenous injection of the probes into nude mice bearing mammary fat pad (MFP) xenograft tumors of marker expressing cells, and non-expressing cells or by pre-injection of unlabeled antibody. To determine whether the probes can be delivered through the lymphatics and detect ALN metastases, luciferase expressing MDA-mb-231 cells that endogenously express CAIX, and luciferase expressing MDA-mb-231 engineered cells to express CAXII were used to form spontaneous ALN metastases from primary mammary fat pad tumors. Once ALN metastasis was observed by bioluminescence imaging, the probes were injected pri-tumorally into the MFP and observed to traverse through the MFP into the lymph node. A specific and durable fluorescence signal was observed in target positive metastases out to at least 48 h post-injection, long after completely clearing from the MFP. Sensitivity was determined by implanting varying numbers of CAIX and CAXII expressing cells into the ALN using ultrasound guidance. As few as 1000 cells were successfully detected indicating the high sensitivity of this method. Hence, these imaging probes have potential use for clinical staging of breast cancer. In the future, this approach may be used to deliver nanoparticles for combined imaging and therapeutic applications. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5301. doi:10.1158/1538-7445.AM2011-5301
Transforming Growth Factor β as a Predictor of Liver and Lung Fibrosis after Autologous Bone Marrow Transplantation for Advanced Breast Cancer
Authors: Mitchell S. Anscher, William P. Peters, Herbert Reisenbichler, William P. Petros, Randy L. Jirtle
Journal: New England Journal of Medicine (1993)

Hepatic veno-occlusive disease and idiopathic interstitial pneumonitis are major causes of morbidity and mortality after bone marrow transplantation. Fibrosis is a characteristic of both conditions, and transforming growth factor β (TGFβ) has been implicated in the pathogenesis of fibrosis.
SP0188 Structural progression in RA remission: Can MRI predict it?
Authors: F. Gandjbakhch
Journal: Annals of the Rheumatic Diseases (2013)

Remission has become in the last few years an accessible objective in the management of rheumatoid arthritis (RA) patients due to treatment improvement and the development of international guidelines. The aim of rheumatoid arthritis treatment is to achieve remission and to stop the progression of structural damage. Different definitions of remission exist. Most of them take into account clinical and biological features and refer to low clinical and biological inflammation states (DAS28, DAS, SDAI, CDAI, ACR/EULAR remission criteria ...). Several studies have shown that patients in clinical remission or low disease activity (LDA) state may show structural progression on radiography. More sensitive tools than clinical examination and radiography are needed to identify RA patients in clinical remission or LDA state at risk of structural progression in order to adapt treatment. MRI, which has a high sensitivity for detecting inflammation and erosion, could be useful in this respect. Disclosure of Interest None Declared
TC-99M TETROFOSMIN IMAGING OF, MYOCARDIAL PERFUSION DURING COCAINE-INDUCED CHEST PAIN.
Authors: J. R. Overbeck, D. A. Hinchman, None Rose-Wolf, D. H. Lewis, M. M. Graham, F. A. DeRook
Journal: Clinical Nuclear Medicine (1999)

Overbeck, J.; Hinchman, D. A.; Rose-Wolf, ; Lewis, D. H.; Graham, M. M.; DeRook, F. A. Author Information
Abstract 418: Cellular mechanisms underlying the evasion of detachment-induced cell death in inflammatory breast cancer cells
Authors: Brittany L. Angarola, Zachary T. Schafer
Journal: Cancer Research (2011)

Abstract Inflammatory Breast Cancer (IBC) is a rare and aggressive form of breast cancer that results from cancerous epithelial cells that invade and block the lymphatic vessels. Because the cancerous cells have already migrated from the epithelium into the lymphatic system, these cells are inherently metastatic and have the ability to survive in the absence of attachment to the extracellular matrix (ECM). Non-cancerous epithelial cells require ECM attachment for normal cell signaling and survival, however IBC cells are able to persist without ECM attachment in the lymphatic vessels. Here we demonstrate that both the SUM149 and the ErbB2-overexpressing SUM190 cell lines derived from primary IBC tumors have acquired mechanisms to aid in their survival in detached environments. Using an in vitro model of ECM detachment, we reveal that detached IBC cells exhibit a dramatic evasion of anoikis (detachment-induced apoptosis). In the SUM149 cells, this evasion of anoikis seems to be mediated by the MAPK pathway as inhibition of this pathway with UO126 abrogates the inhibition of detachment-induced caspase activation. However, the evasion of anoikis in SUM190 cells is unaffected by U0126 treatment and is instead mediated by the PI(3)K pathway. Furthermore, when compared to the SUM149 cells, the SUM190 cells are much more effective at inhibiting anoikis. Interestingly, SUM190 cells exhibit a complete inhibition of the ECM-detachment-induced increase in pro-caspase-3, a mechanism that may explain the more efficient anoikis inhibition in these cells. Additionally, both the SUM149 cells and the SUM190 cells are able to overcome detachment-induced metabolic stress. This is demonstrated through the ability of both the SUM149 and SUM190 cells to maintain ATP levels upon detachment. However, while western blotting clearly demonstrates detachment-induced PI(3)K activation in both cell lines, we have discovered that this upregulation is necessary for metabolic rescue only in the SUM149 cell line. Neither the MAPK nor PI(3)K pathway is involved in the maintenance of ATP following ECM detachment, suggesting that these cells may utilize an alternative signaling pathway to maintain ATP levels. These results show that IBC cells have the capacity to alter both apoptotic and metabolic pathways to survive in detached environments. Further elucidation of these mechanisms may reveal new chemotherapeutic targets that permit the specific elimination of detached IBC cells within the lymphatic system. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 418. doi:10.1158/1538-7445.AM2011-418
The Response to Catechol Amine Infusion During Salicylate-Induced Hypermetabolism in Man
Authors: ROBERT J. T. JOY, FRANK K. AUSTEN
Journal: Circulation Research (1958)

The increase in oxygen consumption produced in man by salieylate administration is not associated with a rise in pulse rate or an increase in responsiveness to infusions of epinephrine or norepinephrine. It is suggested that the effects of thyroid hormone on the cardiovascular system are more dependent on the concentration of circulating thyroid hormone per se than on the concomitant increase in tissue oxygen consumption.
Case 30-2004
Authors: Peter W. Marks, Lawrence R. Zukerberg
Journal: New England Journal of Medicine (2004)

A 37-year-old woman noted a gradual onset of numbness, first in her hands and then in her feet and legs, accompanied by weakness of the legs and difficulty balancing. She was otherwise well except for hypothyroidism, which had developed at the age of 15 years. On examination, there was decreased vibratory sensation and proprioception in the feet. A diagnostic test was performed.
Meckel's ileitis versus Crohn's ileitis: diagnosis using balloon enteroscopy
Authors: M. Velosa, H. Cardoso, E. Rios, G. Macedo
Journal: Endoscopy (2012)

An 18-year-old man presented with a self-limiting episode of abdominal pain and bloody diarrhea for 5 days. During the following year, he reported similar episodes. We performed a colonoscopy that showed normal colonic mucosa with erythema and a few erosions at the ileum. Histology revealed a nonspecific inflammatory infiltrate in the lamina propria. He was treated with prednisolone with initial symptomatic relief, but was admitted to our hospital 3 weeks later, during prednisolone tapering, because of recurrent symptoms and weight loss of 3 kg. He had been an active smoker since the age of 12.
PTU-154 Differences In Coeliac Serology Outcomes Appear Dependant Upon The Origin Of The Request: A Seven Year Review Of Anti-tissue Transglutaminase Testing
Authors: K Bundhoo, D Housley, D Gordon, K Rostami, M Johnson
Journal: Gut (2014)

<h3>Introduction</h3> Coeliac disease is the most common genetically based food intolerance worldwide with a UK prevalence of 1 in 150. The condition poses a diagnostic difficulty due to the often non-specific symptoms at presentation and a sub-group who will be asymptomatic. Successful diagnosis is based upon a high degree of suspicion, correct screening and a subsequent confirmatory test with an intestinal biopsy. Serological testing via anti-endomysial antibody (AEA) and anti-tissue transglutaminase (ATTG) is a simple, highly accurate method of screening, with a sensitivity and specificity in the region of 95–98% and 95–97%, respectively. Due to these attributes, serological screening accounts for a significant proportion of laboratory workloads nationwide. <h3>Methods</h3> All ATTG coeliac serology requests made in a busy district general hospital over a 7 year period between 2007 and 2013 were reviewed, with a particular focus upon the positive results. A further assessment of case records and in particular the origin of requester was conducted. A positive result was issued by the laboratory if the ATTG was greater than or equal to 4. <h3>Results</h3> Overall, a total of 29795 ATTG requests were made to the biochemistry department, of which results were obtained from 28819. Of this number, 1005 were performed in inpatients, 7140 in outpatients and 20674 were from primary care. In the GP cohort, 785/20674 (3.8%) proved to be positive. In comparison 37/1005 (3.7%) were positive from the inpatient group, and 371/7140 (5.2%) were positive from the outpatient cohort. The deficit in results gained was primarily due to the rejection of samples by the laboratory as being “not indicated” in 402 inpatient cases (27%) and 4 outpatient cases. No GP requests were rejected. The overall numbers of ATTG requests also increased year on year with 913 being performed in 2008 and 6483 in 2013. <h3>Conclusion</h3> It is clear the demand for coeliac serology is increasing with its use becoming more widespread in a variety of clinical settings. The mere fact that patients are presenting to hospitals for outpatient appointments or inpatient assessments, places them in a self selecting group where one would expect to see a higher frequency of positive coeliac serology. This was duly noted in our outpatient cohort, but the inpatients had a similar positive pick up rate to the GP cohort. It is possible this result was slightly skewed by the high rejection rate seen with inpatient requests. The high positive pick up rate from specialist outpatient clinics emphasises the importance of having a high degree of clinical suspicion in order to make an appropriate diagnosis. <h3>Disclosure of Interest</h3> None Declared.
Poster session 3. Drug profiles - preclinical
Authors: M. Koronkiewicz, A. Romiszewska, Z. Kazimierczuk, Z. Chilmonczyk, M. D. S. Neto, S. P. Ramos, R. Curvello, M. Bin, N. L. C. Domingues, A. W. Rinaldi, A. C. S. de Souza, S. A. Dyshlovoy, S. Venz, A. Guzii, T. Makarieva, K. Tabakmakher, V. Stonik, S. Balabanov, C. Bokemeyer, F. Honecker, S. Flis, K. Flis, M. Statkiewicz, R. Curvello, M. D. S. Neto, S. P. Ramos, M. E. L. Bin, S. M. Shishido, A. C. S. de Souza, S. Dovat, C. Song, C. Gowda, L. Petrovic-Dovat, J. Payne, L. T. Chen, H. J. Tsai, S. H. Kuo, A. L. Cheng, J. Chen, L. Fu, D. Kwong, X. Guan, S. Zalietok, O. Samoylenko, O. Zhuravel, L. Gulua, O. Orlovsky, V. Chekhun, V. Chekhun, S. Zalietok, L. Gulua, O. Orlovsky, V. Milinevska, O. Karnaushenko, S. Priya, R. S. Reshma, S. N. Rakesh, K. H. Sreelatha, S. Veena, K. Nand, J. C. Gupta, A. K. Panda, S. K. Jain, G. P. Talwar, P. Riva, P. Oreal, R. T. Lima, D. Sousa, K. Choosang, P. Pakkong, A. Palmeira, A. M. Paiva, H. Seca, F. Cerqueira, M. Pedro, M. M. Pinto, E. Sousa, M. H. Vasconcelos
Journal: Annals of Oncology (2013)